BofA/Merrill Lynch Upgrades Amylin Pharmaceuticals (AMLN) to Neutral
Tweet Send to a FriendGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
3 Buy, 8 Hold, 4 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade AMLN Now!
BofA/Merrill Lynch upgraded Amylin Pharmaceuticals (NASDAQ: AMLN) from Underperform to Neutral. PT increased from $11 to $16.
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $13.71 yesterday, with a 52 week range of $9.51-$22.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For more ratings news on Amylin Pharmaceuticals click here and for the rating history of Amylin Pharmaceuticals click here.
Shares of Amylin Pharmaceuticals closed at $13.71 yesterday, with a 52 week range of $9.51-$22.09.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: A.G. Lafley Gives Procter & Gamble (PG) Investors 'New Hope', UBS Upgrades to Buy
- Wedbush Downgrades salesforce.com (CRM) to Neutral
- CL King Upgrades Columbus McKinnon (CMCO) to Buy
Create E-mail Alert Related Categories
UpgradesRelated Entities
Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
